8 completed, 2 terminated. 7 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 5, Terminated 2 |
| Phase 1 | 3 | Completed 3 |
Follow temelimab: new trials by email Literature Review of temelimab trials Research Report on temelimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome Temelimab 54mg/kg, Placebo - Post-COVID-19 Syndrome | Phase 2 | Completed | GeNeuro SA | 203 | 2022-08-29 | 2024-05-17 |
| A Long-term Extension of Study GNC-401 Temelimab 18 mg/kg, Temelimab 36mg/kg, Temelimab 54 mg/kg - Multiple Sclerosis | Phase 2 | Terminated | GeNeuro Innovation SAS | 33 | 2021-08-27 | 2022-07-07 |
| Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis temelimab 18 mg/kg, temelimab 36 mg/kg, temelimab 54 mg/kg - Multiple Sclerosis | Phase 2 | Completed | GeNeuro Innovation SAS | 41 | 2020-06-17 | 2024-11-07 |
| Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers GNbAC1, GNbAC1 Placebo - Multiple Sclerosis | Phase 1 | Completed | GeNeuro Australia PTY Ltd | 24 | 2018-05-08 | 2020-10-20 |
| Clinical Trial Assessing the GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years GNbAC1, Placebo - Diabetes Mellitus Type 1 | Phase 2 | Completed | GeNeuro Australia PTY Ltd | 64 | 2017-06-14 | 2020-10-20 |
| Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis GNbAC1 Monoclonal Antibody - Multiple Sclerosis, Relapsing-Remitting | Phase 2 | Terminated | GeNeuro SA | 220 | 2017-06-06 | 2020-10-20 |
| Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS GNbAC1, Placebo - Multiple Sclerosis, Relapsing-Remitting | Phase 2 | Completed | GeNeuro SA | 270 | 2016-04-01 | 2020-10-20 |
| Safety Study of GNbAC1 Monoclonal Antibody in Healthy Male Volunteers GNbAC1 - Healthy Volunteers | Phase 1 | Completed | GeNeuro Innovation SAS | 21 | 2015-04-01 | 2020-10-20 |
| Safety Study of GNbAC1 in Multiple Sclerosis Patients GNbAC1, GNbAC1 placebo - Multiple Sclerosis | Phase 2 | Completed | GeNeuro Innovation SAS | 10 | 2012-07-01 | 2021-02-08 |
| First-in-Human Study With GNbAC1 in Healthy Volunteers GNbAC1, GNbAC1 placebo - Multiple Sclerosis | Phase 1 | Completed | GeNeuro Innovation SAS | 33 | 2011-07-01 | 2020-10-20 |
Multiple Sclerosis (8) · Multiple Sclerosis, Relapsing-Remitting (2) · Diabetes Mellitus, Type 1 (1) · Post-Acute COVID-19 Syndrome (1)
GeNeuro Innovation SAS (5) · GeNeuro SA (3) · GeNeuro Australia PTY Ltd (2)
Germany (3) · Italy (3) · Spain (3) · Australia (2) · Bulgaria (2) · Croatia (2) · Czechia (2) · Estonia (2) · Hungary (2) · Poland (2) · Russia (2) · Serbia (2) · Sweden (2) · Switzerland (2) · Ukraine (2)
David Leppert, MD (2) · Georg Golor, MD (1) · Patrice Lalive, MD (1) · Thierry Kamtchoua, M.D (1) · Tobias Derfuss, MD (1)
PMID 34240656, PMID 23200102, PMID 25392325, PMID 31311668, PMID 42409185
2014 (1), 2015 (1), 2019 (1)